Globalization and Clinical Research in Latin America

Research Ethics Forum

Volumn 2, Issue , 2014, Pages 55-78

  Homedes, Nuria ^a   Ugalde, Antonio ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Latin American Country; Latin American Population; Market Authorization; Recruitment Center; Study Sponsor

Indexed keywords

EID: 84943159831     PISSN: 22129529     EISSN: 22129537     Source Type: Book Series    
DOI: 10.1007/978-3-319-01363-3_3     Document Type: Chapter

References (55)

1. Amnesty International. 2003. A bitter pill. Amnesty International Magazine, Summer.
2. Association of Clinical Research Organizations (ACRO). nd. CRO Market. www.acrohealth.org/ cro-market1.html. Accessed 28 Oct 2012.
3. Bailey, W., C. Cruickshank, and N. Sharma. 2006. Make your move: Taking clinical trials to the best location. A.T. Kerney Executive Agenda, 56–62. http://www.atkearney.com/main.taf? p¼5,1,1,116,3,1/. Accessed 30 June 2009.
4. Bloch, M., A. Dhankhar, and S. Narayanan. 2006. Pharma leaps offshore. McKinsey and Company. http://www.mckinseyquarterly.com/Pharma_leaps_offshore_1787. Accessed 28 Oct 2012.
5. Bruce, F. 2008. Latin America: Ripe for clinical research? Scrip 100, December 8, 92–93. http://content.yudu.com/Ay6ty/Scrip-100-Dec08/resources/92.htm. Accessed 28 Oct 2012.
6. Center Watch Newsonline. 2006. Fighting the Logjam in LatAm Drug Trials, September 18. http://www.centerwatch.com/news-online/article/573/fighting-the-logjam-in-latam-drug-trials. Accessed 28 Oct 2012.
7. Charlish, P., and S. Fritsch. 2009. All they’re cracked up to be? Scrip 100, Sript’s analysis of the pharmaceutical industry’s performance and prospects. London: Informa UK, December, 115–117.
8. CIOMS. 2002. International ethical guidelines for biomedical research involving human subjects. http://www.cioms.ch/publications/layout_guide2002.pdf. Accessed 28 Oct 2012.
9. Clarín. 2002. Un informe sobre ética en las investigaciones con pacientes oncológicos de la defensoría del pueblo de la nación de Argentina denuncia que el estado no controla pruebas de drogas en pacientes con cáncer (A report by the Argentina’s national ombudsman regarding the ethics of research on cancer patients denouncing that the government does not control clinical trials), May 22. http://www.saludyfarmacos.org/lang/es/boletin-farmacos/boletines/jun2003/etica-y-medicamentos/. Accessed 28 Oct 2012.
10. Cutting Edge Information. 2009. Strategic Clinical outsourcing. Selecting partners and managing relationships. http://www.cuttingedgeinfo.com/research/clinical-development/outsourcing-selection-strategy/. Accessed 26 Oct 2012.
11. David, E., T. Tramontin, and R. Zemmel. 2010. The road to positive R&D returns. McKinsey Quarterly. http://www.mckinseyquarterly.com/The_road_to_positive_R_and_D_returns_2528. Accessed 28 Oct 2012.
12. Department of Health and Human Services. Office of Inspector General. 2007. The Food and Drug Administration’s oversight of clinical trials. OEI-01-06-00160. https://oig.hhs.gov/oei/reports/oei-01-06-00160.pdf. Accessed 28 Oct 2012.
13. Department of Health and Human Services. Office of Inspector General. 2010. Challenges to FDA’s ability to monitor and inspect foreign clinical trials. OEI-01-08-00510. http://www. healthlawyers.org/News/Health%20Lawyers%20Weekly/Documents/06_25_10/oei-01-08-00510.pdf. Accessed 28 Oct 2012.
14. Department of Health and Human Services. Office of Inspector General. Recruiting Human Subjects. 2000. Pressures in industry-sponsored clinical research. OEI-01-97-00195. http://firstclinical.com/regdocs/doc/?db¼OTH_OEI_01_97_00195. Accessed 28 Oct 2012.
15. Downing, G. 2009. Designation of clinical research information integration as an objective of “meaningful use” of electronic health record systems. Presentation to the HIT Policy Committee, Office of the Secretary. Department of Health and Human Services, 28 Oct. http://healthit. hhs.gov/portal/server.pt/gateway/PTARGS_0_10741_907422_0_0_18/Downing-UMPClincalResearch.pdf. Accessed 28 Oct 2012.
16. Freitas, C.B.D. 2006. O sistema de avaliação da ética em pesquisa no Brasil:estudo dos conhecimentos e prácticas de lideranças de Comités de Ética em Pesquisa (System of research ethics evaluation in Brazil: Study of knowledge and practices of leadership of research ethics committees). Dissertation, Universidad de Sao Paolo.
17. Fuentes, D., and D Revilla. 2007. Acreditación de comités de ética en investigación, como parte de un proceso (The process of accreditation of research ethics committees). Anales de la Facultad de Medicina (Peru) 68(1): 67–74. http://sisbib.unmsm.edu.pe/bvrevistas/anales/v68n1/pdf/a09v68n1.pdf
18. Garattini, S., and V. Bertele. 2007. Non-inferiority trials are unethical because they disregard patients’ interests. Lancet 370: 1875–1877.
19. Glickman, S.W., J.G. McHutchison, E.D. Peterson, et al. 2009. Ethical and scientific implications of the globalization of clinical research. New England Journal of Medicine 360: 816–823.
20. Government Accountability Office (GAO). 2009. Human subjects research: Undercover tests show the institutional review board system is vulnerable to unethical manipulation. GAO-09-448T. http://www.gao.gov/products/GAO-09-448T. Accessed 27 Oct 2012.
21. Hanauer, S.B. 2009. Outsourcing clinical trials. Nature Reviews Gastroenterology and Hepatology 6: 191.
22. Hurley, D., M. Lipezker, H. Melgar, et al. 2009. Latin American clinical trial authorizations. Overview and update. Regulatory Focus 38–42.
23. ICH. 1996. Guidance for the industry. E6 good clinical practice: Consolidated guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf. Accessed 22 Sept 2012.
24. Karlberg, J.P.E. 2008a. Industry clinical testing of new medicinal products requires 95.000 study sites and 1,300.000 subjects annually. Clinical Trial Magnifier 1(6): 101–109.
25. Karlberg, J.P.E. 2008b. Globalization of sponsored clinical trials. Nature Reviews Drug Discovery 7: 458. doi:10.1038/nrd2441-c1.
26. Karlberg, J.P.E. 2009a. What is driving the globalization process of clinical research? Clinical Trials Magnifier 2(8): 396–397.
27. Karlberg, J.P.E. 2009b. Office of human research protection assurance. Clinical Trials Magnifier 2 (8): 418–433.
28. Karlberg, J.P.E. 2009c. USFDA site inspections findings, 1997–2008, fail to justify globalization concerns. Clinical Trial Magnifier 2(4): 194–212.
29. Kline, D. 2001. Clinical trials in Latin America. DataEdge. http://www.fast-track.com/pdfs/ClinicalTrialsLatinAmerica.pdf. Accessed 27 Oct 2012.
30. Marshall, E. 2008. Lemons, oranges, and complexity. Science 322: 209.
31. McDonald, A.M., R.C. Knight, M.K. Campbell, et al. 2006. What influences recruitment to randomised controlled trials: A review of trials funded by two UK funding agencies. Trials 7(1): 9.
32. Medical News Today. 2005. US Drug companies conducting more clinical trials overseas to reduce costs, speed approval. Medical News Today, 18 May. www.medicalnewstoday.com/ articles/24634.php. Accessed 27 Oct 2012.
33. National Cancer Institute. 2008. Initiative to speed clinical trial negotiations moves forward. NCI Bulletin 5: 20. http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2008/100708/page1. Accessed 27 Oct 2012.
34. Nishioka, S.A. 2006. Regulação de pesquisa clínica no Brasil: passado, presente e futuro (Regula-tion of clinical research in Brazil: Past, present and future). Prática Hospitalar 8(48): 17–26.
35. Normile, D. 2008. The promise and pitfalls of clinical trials overseas. Science 322: 214–216.
36. Novaes, M.R., D. Guilhem, and F. Lolas. 2008. Dez anos de experiência do comitê de ética em pesquisa da Secretaria de Saúde do Distrito Federal, Brasil. Acta Bioethica 14(2): 185–192.
37. Pan American Health Organization. 2007. Health in the Americas. Washington, DC: PAHO.
38. Perel, P., J.P. Casas, Z. Ortiz, and J.J. Miranda. 2006. Noncommunicable diseases and injuries in Latin America and the Caribbean: Time for action. PLoS Medicine 3(9): e34.
39. Petinelli, A. 2005. Irregularidades en proyecto epidemiológico (Irregularities in epidemiological project). Boletín Fármacos 8(4): 107–110.
40. RAPS Webcasts. 2009. Drug development in Latin America. Recent trends and competitive advantage. http://www.docstoc.com/docs/50709074/Webcast_FocusLatam_1_. Accessed 28 Oct 2012.
41. Rivera, R., and E. Ezcurra. 2001. Composition and operation of selected research ethics review committees in Latin America. IRB Ethics and Human Research 23(5): 9–12.
42. Rodrigues, D.G. 2007. Clinical research and drug development in Latin America: Weighing the pros and cons, talking about the future. Journal of Investigative Medicine 55: 223–229.
43. Rowland, C. 2004. Clinical trials seen shifting overseas. International Journal of Health Services 34(3): 555–556.
44. Thiers, F.A., A.J. Sinskey, and E.R. Berndt. 2008. Trends in the globalization of clinical trials. Nature Reviews Drug Discovery 7: 13–14.
45. Treweek, S., E. Mitchell, M. Pitkethly, et al. 2010. Strategies to improve recruitment to randomized controlled trials. Cochrane Database System Review 4. http://www. thecochranelibrary.com/userfiles/ccoch/file/INternational%20Clinical%20Trials%20Day/MR000013.pdf. Accessed 27 Oct 2012.
46. UNESCO. 2005. Declaración Universal de Bioética y Derechos Humanos. Paris: UNESCO. http://unesdoc.unesco.org/images/0014/001461/146180s.pdf. Accessed 27 Oct 2012.
47. Valdez-Martínez, E., J. Garduño-Espinosa, H. Martinez-Salgado, et al. 2004. Local research ethics committees of the Mexican Institute of Social Security: Results of a national survey. Public Health 118: 329–336.
48. Valdez-Martínez, E., B. Turnbull, J. Garduño-Espinosa, et al. 2005. Understanding the structure and practices of research ethics committees through research and audit: A study from Mexico. Health Policy 74(1): 56–68.
49. Valdez-Martínez, E., B. Turnbull, J. Garduño-Espinosa, et al. 2006. Descriptive Ethics: A qualitative study of local research ethics committees in Mexico. Developing World Bioethics 6(2): 95–105.
50. Valdez-Martínez, E., A. Lifshitz-Guinzberg, and J. Medesigo-Micete. 2008. Los comités de ética clínica en México: la ambigua frontera entre la ética asistencial y la ética en investigación clínica (The clinical ethics committees in Mexico: Unclear frontier between ethical assistance and clinical research ethics). Revista Panamericana de Salud Pública 24(2): 85–90.
51. Value of Insight (VOI). 2009. The case for globalization: Ethical and business considerations in clinical research. https://www.voiconsulting.com/sites/default/files/publication-popups/Clini cal%20Trials%20Globalization%20-%20ACRO.pdf. Accessed 27 Oct 2012.
52. Vargas-Parada, L., S. Kawa, A. Salazar, et al. 2006. Informed consent in clinical research at a general hospital in Mexico: Opinions of the investigators. Developing World Bioethics 6(1): 41–51.
53. Virk, K.P. 2009. Latin America’s trials climate. Applied Clinical Trials online. http://license. icopyright.net/user/viewFreeUse.act?fuid¼ODg1NDQwNg%3D%3D. Accessed 27 Oct 2012.
54. World Medical Association. nd. Declaration of Helsinki. http://www.wma.net/en/30publications/10policies/b3/
55. WTO. 1994. Agreement on trade-related aspects of intellectual property rights. Annex 1C. http://www.wto.org/english/docs_e/legal_e/27-trips.pdf. Accessed 22 Sept 2012.